Rezolute, Inc.
  • About Us
    • Mission
    • Leadership
    • Contact
  • Our Focus
    • Hyperinsulinism Therapeutics
    • Publications & Presentations
  • Our Pipeline
    • Development Pipeline
    • Ersodetug
    • Clinical Trials
  • Join Us
    • Our Culture
    • Job Openings
  • Investors & Media
    • Investors Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Stock Quote & Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Investor Contacts
  • for patients
    • Understanding Hyperinsulinism
    • Join the Rezolution
Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • chevron_leftBack to rezolutebio.com
  • Investors Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Stock Quote & Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Investor Contacts

Press Releases

Investors

Investors

  • Investors Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Stock Quote & Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Investor Contacts
Oct 20, 2022 7:00 am EDT
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
Sep 15, 2022 4:05 pm EDT
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
Sep 7, 2022 7:00 am EDT
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
Jun 1, 2022 7:00 am EDT
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
May 12, 2022 4:05 pm EDT
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
May 4, 2022 4:01 pm EDT
Rezolute to Host Corporate Update Call on May 4, 2022
May 4, 2022 9:33 am EDT
Rezolute, Inc. Announces Closing of Registered Direct Offering
May 1, 2022 11:25 pm EDT
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
May 1, 2022 2:00 pm EDT
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Apr 26, 2022 4:05 pm EDT
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • …
  • Page 17
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
Footer logo

Join our passionate and dedicated team to make a difference for patients.

SEE OPEN JOBS
  • About Us
    • Mission
    • Leadership
    • Contact
  • Our Focus
    • Hyperinsulinism Therapeutics
    • Publications & Presentations
  • Our Pipeline
    • Development Pipeline
    • Ersodetug
    • Clinical Trials
  • Join Us
    • Our Culture
    • Job Openings
  • Investors & Media
    • Investors Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Stock Quote & Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Investor Contacts
  • for patients
    • Understanding Hyperinsulinism
    • Rezolution Community
©2025 Rezolute, Inc. All rights reserved. Privacy Policy Terms of Use
Made by 22 Fillmore